Xiao Jia Cai
Fondateur chez Thornton Consulting Group
Profil
Xiao Jia Cai is the founder of Thornton Consulting Group.
She currently holds director positions at the Science History Institute, Spectral MD, Inc., Basking Biosciences, Inc., Amberstone Biosciences, Inc., AceLink Therapeutics, Inc., F5 Therapeutics, Inc., and Exarta Therapeutics.
Previously, she served as a director at Arthrosi Therapeutics, Inc. and as an independent non-executive director at Spectral MD Holdings Ltd.
She also held the position of independent director at Spectral AI, Inc. from 2023 to 2024.
Additionally, Dr. Cai was an associate vice president at Agilent Technologies, Inc. She obtained an MBA from the University of Pennsylvania, a doctorate from the University of Massachusetts, and completed undergraduate and graduate studies at Tsinghua University.
Postes actifs de Xiao Jia Cai
Sociétés | Poste | Début |
---|---|---|
Thornton Consulting Group | Fondateur | - |
Spectral MD, Inc.
Spectral MD, Inc. Pharmaceuticals: MajorHealth Technology Spectral MD, Inc. engages in the manufacture of medical devices. It focuses on the modernization of wound care offering DeepView a wound imaging system. The company was founded by J. Michael DiMaio and is headquartered in Dallas, TX. | Directeur/Membre du Conseil | - |
F5 Therapeutics, Inc. | Directeur/Membre du Conseil | - |
AceLink Therapeutics, Inc.
AceLink Therapeutics, Inc. BiotechnologyHealth Technology AceLink Therapeutics, Inc. is a biopharmaceutical startup founded in 2018 that focuses on developing safe and effective medicines to address genetic diseases with high unmet needs. AceLink Therapeutics is based in Newark, CA. The private company's initial focus is on developing novel therapeutics for Fabry disease and type 1 Gaucher disease. The company was founded in 2018 by Wen Chen, Marvin R. Garovoy, and Jerry Shen. Jerry Shen has been the CEO since 2018. | Directeur/Membre du Conseil | - |
Exarta Therapeutics | Directeur/Membre du Conseil | - |
Amberstone Biosciences, Inc.
Amberstone Biosciences, Inc. BiotechnologyHealth Technology Amberstone Biosciences, Inc. is a company that aims to eliminate the issues of dose toxicity interfering with drug efficacy by introducing a safer class of therapeutic agents. The company is based in Laguna Hills, CA. The company's team of scientists and engineers strives to discover and develop transformative immunotherapeutics, pioneering a new wave of therapeutic breakthroughs. The company is developing first-in-class tumor microenvironment activated therapeutic (T-MATE). The company was founded in 2018 by Guikai George Wu. Guikai George Wu has been the CEO since 2018. | Directeur/Membre du Conseil | - |
Science History Institute | Directeur/Membre du Conseil | - |
Basking Biosciences, Inc.
Basking Biosciences, Inc. BiotechnologyHealth Technology Basking Biosciences, Inc. is a clinical-stage company that aims to solve the biggest need in ischemic stroke therapy. The company is based in Columbus, OH. The company is developing a first-in-class RNA aptamer targeting von Willebrand factor (vWF), an important structural component of blood clots and driver of the clotting process. Basking is also developing a complementary rapid-acting reversal oligonucleotide capable of quickly neutralizing the pharmacological activity of the RNA aptamer. The company has successfully completed a phase 1 single-ascending dose safety study and is initiating a phase 2 clinical proof-of-concept study in patients suffering from an acute ischemic stroke. The ultimate goal is to extend the therapeutic window for thrombolysis compared to currently approved therapies. Basking Biosciences was founded in 2019 by Shahid Nimjee, Bruce A. Sullenger, and Richard J. Shea has been the CEO of the company since 2019. | Directeur/Membre du Conseil | - |
Anciens postes connus de Xiao Jia Cai
Sociétés | Poste | Fin |
---|---|---|
SPECTRAL AI, INC. | Directeur/Membre du Conseil | 14/05/2024 |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
░░░░░░░░ ░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Xiao Jia Cai
University of Pennsylvania | Masters Business Admin |
University of Massachusetts | Doctorate Degree |
Tsinghua University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
AGILENT TECHNOLOGIES, INC. | Health Technology |
SPECTRAL AI, INC. | Health Technology |
Entreprise privées | 10 |
---|---|
Science History Institute | Process Industries |
Arthrosi Therapeutics, Inc.
Arthrosi Therapeutics, Inc. BiotechnologyHealth Technology Arthrosi Therapeutics, Inc. engages in the development of biotechnology treatment. The company was founded in 2017 and is headquartered in Laguna Hills, CA. | Health Technology |
Spectral MD, Inc.
Spectral MD, Inc. Pharmaceuticals: MajorHealth Technology Spectral MD, Inc. engages in the manufacture of medical devices. It focuses on the modernization of wound care offering DeepView a wound imaging system. The company was founded by J. Michael DiMaio and is headquartered in Dallas, TX. | Health Technology |
Basking Biosciences, Inc.
Basking Biosciences, Inc. BiotechnologyHealth Technology Basking Biosciences, Inc. is a clinical-stage company that aims to solve the biggest need in ischemic stroke therapy. The company is based in Columbus, OH. The company is developing a first-in-class RNA aptamer targeting von Willebrand factor (vWF), an important structural component of blood clots and driver of the clotting process. Basking is also developing a complementary rapid-acting reversal oligonucleotide capable of quickly neutralizing the pharmacological activity of the RNA aptamer. The company has successfully completed a phase 1 single-ascending dose safety study and is initiating a phase 2 clinical proof-of-concept study in patients suffering from an acute ischemic stroke. The ultimate goal is to extend the therapeutic window for thrombolysis compared to currently approved therapies. Basking Biosciences was founded in 2019 by Shahid Nimjee, Bruce A. Sullenger, and Richard J. Shea has been the CEO of the company since 2019. | Health Technology |
Spectral MD Holdings Ltd.
Spectral MD Holdings Ltd. Packaged SoftwareTechnology Services Spectral MD Holdings Ltd. develops proprietary artificial intelligence algorithms and optical technology to help clinicians to make faster treatment decisions in wound care sector. Its DeepView Wound Imaging solution is an internally developed AI and multispectral imaging technology that enables the user to distinguish between damaged and healthy human tissue. The company was founded in 2009 and is headquartered in Dallas, TX. | Technology Services |
Amberstone Biosciences, Inc.
Amberstone Biosciences, Inc. BiotechnologyHealth Technology Amberstone Biosciences, Inc. is a company that aims to eliminate the issues of dose toxicity interfering with drug efficacy by introducing a safer class of therapeutic agents. The company is based in Laguna Hills, CA. The company's team of scientists and engineers strives to discover and develop transformative immunotherapeutics, pioneering a new wave of therapeutic breakthroughs. The company is developing first-in-class tumor microenvironment activated therapeutic (T-MATE). The company was founded in 2018 by Guikai George Wu. Guikai George Wu has been the CEO since 2018. | Health Technology |
AceLink Therapeutics, Inc.
AceLink Therapeutics, Inc. BiotechnologyHealth Technology AceLink Therapeutics, Inc. is a biopharmaceutical startup founded in 2018 that focuses on developing safe and effective medicines to address genetic diseases with high unmet needs. AceLink Therapeutics is based in Newark, CA. The private company's initial focus is on developing novel therapeutics for Fabry disease and type 1 Gaucher disease. The company was founded in 2018 by Wen Chen, Marvin R. Garovoy, and Jerry Shen. Jerry Shen has been the CEO since 2018. | Health Technology |
Thornton Consulting Group | |
F5 Therapeutics, Inc. | |
Exarta Therapeutics |